The CREPE Study: PSMA+ Castration Resistant Prostate Cancer in England
Research type
Research Study
Full title
The CREPE Study: Outcomes and Treatment Pathways for PSMA+ Castration Resistant Prostate Cancer in England
IRAS ID
275308
Contact name
Adrian Paul Rabe
Contact email
Sponsor organisation
Health iQ
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Prostate cancer is an abnormal growth in the prostate that tends to invade surrounding tissue and spread to other parts of the body. There is a form of prostate cancer that does not respond to medications that block the male hormone testosterone. This subset of the disease is termed "castration resistant" prostate cancer. Additionally, some of these patients have a marker called the Prostate Specific Membrane Antigen (PSMA) which further means no response to some medications. Being a very debilitating disease, it is important to understand how much resources patients with PSMA+ castration resistant prostate cancer use up in the national health service, as well as the various treatments they undergo, and how those treatments impact their survival. This study aims to use anonymized and pseudonymized data from Public Health England to construct a group of patients with PSMA+ castration resistant prostate cancer. Using the same dataset linked to secondary care, to the cancer treatment dataset, and the diagnostic imaging dataset, the study would determine healthcare resource use and treatment pathways, as well as clinical outcomes. The span of time covered would be from 2006 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reduce healthcare resources and reconfigure services to provide better treatment pathways for patients.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
19/SC/0595
Date of REC Opinion
29 Nov 2019
REC opinion
Favourable Opinion